International Clinical Trial: Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465718) titled 'Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Orphalan

Condition: Wilson's Disease

Intervention: Drug: TETA 4HCl formulation

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: May 2026

Target Sample Size: 38

To know more, visit https://clinicaltrials.gov/study/NCT07465718

Published by HT Digital Content Services with permis...